29 Apr, 2022 06:48 PM
* Quarterly customer receipts of A$3.8m. However, a further $1.0m of receipts were subject to a logistics delay beyond our control and therefore revenue will be recognised in the next quarter. This ...read more
29 Apr, 2022 12:24 PM
Highlights:
* Careteq achieves several milestones in the quarter and advances on significant opportunities in Australia and North America, as highlighted in Careteq’s prospectus
* Further ...read more
27 Apr, 2022 11:53 AM
Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to provide a summary of its activities for the quarter ended 31...read more
25 Mar, 2022 09:47 AM
On 21 February 2022, Chimeric Therapeutics Limited (ASX:CHM) (Chimeric or Company) announced the details of an accelerated non-renounceable 1 for 3.15 entitlement offer (Entitlement Offer).
Chime...read more
23 Mar, 2022 02:04 PM
-- A CAR T targeting the cell surface marker CDH17 (“CDH17 CAR”), currently under development by Chimeric as CHM 2101, is featured in the prestigious journal Nature Cancer, highlighting ...read more
23 Mar, 2022 10:03 AM
The securities of Chimeric Therapeutics Limited (‘CHM’) will be placed in trading halt at the request of CHM, pending it releasing an announcement. Unless ASX decides otherwise, the secu...read more
23 Mar, 2022 09:48 AM
On 21 February 2022, Chimeric Therapeutics Limited (ASX:CHM) (Chimeric or Company) announced the details of an accelerated non-renounceable entitlement offer (Entitlement Offer) to raise approximate...read more
21 Mar, 2022 08:56 AM
The options (ASX: CHMO) of Chimeric Therapeutics Limited (‘CHM’) will be suspended immediately, in accordance with Listing Rule 17.3, as deferred settlement trading will not be made avai...read more